Roche Holding AGXSWX:ROP +2.09%80 PB Ratio is 7.81 as of Jun. 25, 2026, which is 4% below its 10-year median of 8.12. GuruFocus rates XSWX:ROP with a GF Score™ of 80/100 and a GF Value™ of CHF264.69 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Roche Holding AG ranks worse than 90.67% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Roche Holding AG's share price is CHF332.00. Roche Holding AG's Book Value per Share for the quarter that ended in Dec. 2025 was CHF42.49. Hence, Roche Holding AG's PB Ratio of today is 7.81.
The historical rank and industry rank for Roche Holding AG's PB Ratio or its related term are showing as below:
XSWX:ROP'
s PB Ratio Range Over the Past 10 Years
Min: 5.91 Med: 8.12 Max: 13.02
Current: 7.82
During the past 13 years, Roche Holding AG's highest PB Ratio was 13.02. The lowest was 5.91. And the median was 8.12.
XSWX:ROP's PB Ratio is ranked worse than 90.67% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs XSWX:ROP: 7.82
During the past 12 months, Roche Holding AG's average Book Value Per Share Growth Rate was 6.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 4.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Roche Holding AG was 27.40% per year. The lowest was -42.80% per year. And the median was 9.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Roche Holding AG PB Ratio Related Terms
Roche Holding AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Roche Holding AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Roche Holding AG (XSWX:ROP) has a PB Ratio of 7.81 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Roche Holding AG and its competitors. This is near median its historical median of 8.12. Over the past decade, Roche Holding AG's PB Ratio has ranged from 5.91 to 13.02. According to the industry distribution chart, Roche Holding AG ranks #836 out of 922 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Roche Holding AG's PB Ratio too high?
Roche Holding AG's current PB Ratio of 7.81 is near median its 10-year median of 8.12. Over the past 10 years, this metric has ranged from a low of 5.91 to a high of 13.02. The Drug Manufacturers industry median PB Ratio is 1.86. Roche Holding AG's value of 7.81 is 321% above this industry median. Based on the distribution chart, Roche Holding AG ranks #836 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Roche Holding AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #836 out of 922 companies for PB Ratio. This places Roche Holding AG in the lower half of its industry. The industry median PB Ratio is 1.86. Roche Holding AG's value of 7.81 is 321% above this benchmark. Historically, Roche Holding AG's own PB Ratio has ranged from 5.91 to 13.02 over the past decade. While the company's 10-year median is 8.12 vs. the industry median of 1.86, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current PB Ratio of 7.81 is 321% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current PB Ratio is 7.81, which is near median its own 10-year median of 8.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:ROP) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF264.69, compared to a current price of CHF332.00 — trading 25.4% above its estimated fair value. The current PB Ratio is 7.81, which is near median its 10-year median of 8.12 and 321% above the Drug Manufacturers industry median of 1.86. Roche Holding AG's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Roche Holding AG (XSWX:ROP), the current PB Ratio is 7.81 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:ROP) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF332.00 is trading 25.4% above its estimated GF Value™ of CHF264.69.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:ROP:
PB Ratio: 7.81 (near median its 10-year median of 8.12)
GF Value™: CHF264.69 vs. price of CHF332.00 (25.4% above fair value)
Industry Position: 321% above the Drug Manufacturers median (#836 of 922)
No single metric tells the full story. See the XSWX:ROP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
80GF Score
Get the complete analysis for XSWX:ROP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ROP has been successfully added to your 
